Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Oncology/Epidemiology
  • Published:

Clinical Oncology/Epidemiology

The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid)

British Journal of Cancer volume 58, pages 189–190 (1988)Cite this article

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. University Department of Clinical Oncology, Newcastle General Hospital, Newcastle upon Tyne, UK

    BMJ Cantwell

Authors
  1. BMJ Cantwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. AL Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cantwell, B., Harris, A. The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid). Br J Cancer 58, 189–190 (1988). https://doi.org/10.1038/bjc.1988.190

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1988.190

This article is cited by

Search

Advanced search

Quick links